CRP and plasma cell myeloma: In 2019, data from NDMM patients enrolled in the randomized Myeloma IX and Myeloma XI trials (ISRCTN.com Registry identifiers: ISRCTN68454111 and ISRCTN49407852) were used to design the UK Myeloma Research Alliance Risk Profile (MRP) [36 The prognostic variables of the score were the World Health Organization (WHO) performance status, age, ISS stage, and circulating levels of C-reactive protein (CRP).